CCLM:磷脂酰丝氨酸/凝血酶原(aPS / PT)抗体提高中国抗磷脂综合征患者的诊断效果

2018-07-05 MedSci MedSci原创

目前,越来越多的证据强调了非标准抗磷脂抗体(aPLs)应该作为当前用于诊断抗磷脂综合征(APS)的标准aPLs的重要补充剂。在这项回顾性研究中,我们评估了中国APS患者抗体与磷脂酰丝氨酸/凝血酶原(aPS / PT)的临床相关性。 研究人员共测试了441名受试者,包括101名患有原发性APS(PAPS)的患者,140名患有继发性APS(SAPS)的患者,161名疾病对照(DC)和39名健康对

目前,越来越多的证据强调了非标准抗磷脂抗体(aPLs)应该作为当前用于诊断抗磷脂综合征(APS)的标准aPLs的重要补充剂。在这项回顾性研究中,我们评估了中国APS患者抗体与磷脂酰丝氨酸/凝血酶原(aPS / PT)的临床相关性。

研究人员共测试了441名受试者,包括101名患有原发性APSPAPS)的患者,140名患有继发性APSSAPS)的患者,161名疾病对照(DC)和39名健康对照(HC)。通过ELISA测定血清IgG / IgM aPS / PT

结果显示,与DCHC相比,APS患者的IgG / IgM aPS / PT水平显著增加。IgGIgM aPS / PT分别存在于29.7%和54.5%的SAPS患者,以及42.1%和53.6%的SAPS患者。对于APS诊断IgG aCL表现出最高的阳性似然比(LR +)为21.60,其次是LA13.84),IgGaβ2GP19.19)和IgG aPS / PT8.49)。在13.3%的血清阴性PAPS患者和31.3%的血清阴性SAPS患者中检测到aPS / PTLA在识别血栓形成患者中表现出最高的OR 3.64,其次是IgG aCLOR2.63),IgG aPS / PTOR2.55)和IgGaβ2GP1OR2.33)。LAIgG aCL与动脉和静脉血栓形成相关,而IgG aPS / PTIgGaβ2GP1分别与静脉或动脉血栓形成相关。

我们的研究结果表明,纳入IgG / IgM aPS / PT可以提高APS的诊断性能,尤其是对于那些高度怀疑APS的人,但传统的aPLs反复阴性。此外,IgG aPS / PT可能有助于识别有血栓形成风险的患者。

原始出处:

Zhang, Shulan, Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1968563, encodeId=86b6196856366, content=<a href='/topic/show?id=2e902103631' target=_blank style='color:#2F92EE;'>#丝氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21036, encryptionId=2e902103631, topicName=丝氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Thu Mar 07 04:58:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415956, encodeId=9bc1141595648, content=<a href='/topic/show?id=6e0631341b6' target=_blank style='color:#2F92EE;'>#凝血酶原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31341, encryptionId=6e0631341b6, topicName=凝血酶原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15d23117049, createdName=gostraight, createdTime=Sat Jul 07 05:58:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431258, encodeId=0bc7143125849, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jul 07 05:58:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482822, encodeId=c932148282254, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Sat Jul 07 05:58:00 CST 2018, time=2018-07-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1968563, encodeId=86b6196856366, content=<a href='/topic/show?id=2e902103631' target=_blank style='color:#2F92EE;'>#丝氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21036, encryptionId=2e902103631, topicName=丝氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Thu Mar 07 04:58:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415956, encodeId=9bc1141595648, content=<a href='/topic/show?id=6e0631341b6' target=_blank style='color:#2F92EE;'>#凝血酶原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31341, encryptionId=6e0631341b6, topicName=凝血酶原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15d23117049, createdName=gostraight, createdTime=Sat Jul 07 05:58:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431258, encodeId=0bc7143125849, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jul 07 05:58:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482822, encodeId=c932148282254, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Sat Jul 07 05:58:00 CST 2018, time=2018-07-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1968563, encodeId=86b6196856366, content=<a href='/topic/show?id=2e902103631' target=_blank style='color:#2F92EE;'>#丝氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21036, encryptionId=2e902103631, topicName=丝氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Thu Mar 07 04:58:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415956, encodeId=9bc1141595648, content=<a href='/topic/show?id=6e0631341b6' target=_blank style='color:#2F92EE;'>#凝血酶原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31341, encryptionId=6e0631341b6, topicName=凝血酶原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15d23117049, createdName=gostraight, createdTime=Sat Jul 07 05:58:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431258, encodeId=0bc7143125849, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jul 07 05:58:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482822, encodeId=c932148282254, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Sat Jul 07 05:58:00 CST 2018, time=2018-07-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1968563, encodeId=86b6196856366, content=<a href='/topic/show?id=2e902103631' target=_blank style='color:#2F92EE;'>#丝氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21036, encryptionId=2e902103631, topicName=丝氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Thu Mar 07 04:58:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415956, encodeId=9bc1141595648, content=<a href='/topic/show?id=6e0631341b6' target=_blank style='color:#2F92EE;'>#凝血酶原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31341, encryptionId=6e0631341b6, topicName=凝血酶原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15d23117049, createdName=gostraight, createdTime=Sat Jul 07 05:58:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431258, encodeId=0bc7143125849, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jul 07 05:58:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482822, encodeId=c932148282254, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Sat Jul 07 05:58:00 CST 2018, time=2018-07-07, status=1, ipAttribution=)]